Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE
15 októbra, 2020 7:26 pmAuthor(s): Timothy Hughes, Carla Boquimpani, Naoto Takahashi, et al Abstract: P 257 Session topic: 8. Chronic myeloid leukemia...
IMPACT OF ARTERIAL THROMBOTIC EVENTS ON THE LONG-TERM OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED IN FIRST-LINE WITH NILOTINIB: AN ANALYSIS OF THE GIMEMA CML WORKING PARTY
15 októbra, 2020 7:26 pmAuthor(s): Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et. al. Abstract: P 605 Session topic: 8. Chronic myeloid leukemia...
Aktuality z EHA 2017 zaměřené na chronickou myeloidní leukemii
15 októbra, 2020 7:26 pmChronická myeloidní leukemie (CML) je klonální myeloproliferativní onemocnění, které představuje 15–25 % nově diagnostikovaných leukemií dospělého věku. Je příkladem onemocnění, u kterého...
COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110)
15 októbra, 2020 7:26 pmAuthor(s): Frank Stegelmann, Martin Griesshammer, Steffen Koschmieder Abstract: P 700 Session topic: 16. Myeloproliferative neoplasms – Clinical ...
PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB, IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) AND BASELINE THROMBOCYTOPENIA: FOCUS ON ANEMIA IN THE PHASE 3 PERSIST-2 TRIAL
15 októbra, 2020 7:26 pmAuthor(s): Moshe Talpaz, John Mascarenhas, Ronald Hoffman Abstract: P 699 Session topic: 16. Myeloproliferative neoplasms – Clinical ...
RUXOLITINIB FOR THE TREATMENT OF INADEQUATELY CONTROLLED POLYCYTHEMIA VERA WITHOUT SPLENOMEGALY: 80-WEEK FOLLOW-UP FROM THE RESPONSE-2 TRIAL
15 októbra, 2020 7:26 pmAuthor(s): Martin Greisshammer, Guray Saydam, Francesca Palandri, et. al. Abstract: S 784 Session topic: 16. Myeloproliferative neoplasms –...
Myeloproliferatívna neoplázia: novinky z kongresu
15 októbra, 2020 7:26 pmV poradí 22. kongres Európskej hematologickej asociácie bol mimoriadne úspešný. Viac ako 10-tisíc delegátov, rekordných 2 500 prihlásených abstraktov, 60 prednášok v rámci...
IS THE SPLENECTOMY OUTCOME PREDICTABLE IN PATIENTS WITH ITP?
15 októbra, 2020 7:26 pmAuthor(s): Mirjana Mitrovic, Slavko Matic, Jelena Bodrozic, et. al. Abstract: E1448 Session topic: 32. Platelets disorders Background:...
SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)
15 októbra, 2020 7:26 pmAuthor(s): James Bussel, Michael Tarantino, Victor Blanchette, et. al. Abstract: P 727 Session topic: 32. Platelets disorders ...
TREATMENT OF PRIMARY ADULT CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) WITH FOSTAMATINIB, AN ORAL SYK INHIBITOR: RESULTS OF TWO RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES
15 októbra, 2020 7:26 pmAuthor(s): J Bussel, J Mayer, L Cervinek, K Chojnowski, et. al. Abstract: S 435 Session topic: 32. Platelets...